| Literature DB >> 33097631 |
Sheryl Roberts1, Eshita Khera2, Crystal Choi1, Tejas Navaratna2, Jan Grimm1,3,4,5, Greg M Thurber2,6, Thomas Reiner7,4,8.
Abstract
Limitations in current imaging tools have long challenged the imaging of small pancreatic islets in animal models. Here, we report the first development and in vivo validation testing of a broad-spectrum and high-absorbance near-infrared optoacoustic contrast agent, E4x12-Cy7. Our near-infrared tracer is based on the amino acid sequence of exendin-4 and targets the glucagon-like peptide-1 receptor (GLP-1R). Cell assays confirmed that E4x12-Cy7 has a high-binding affinity (dissociation constant, Kd, 4.6 ± 0.8 nM). Using the multispectral optoacoustic tomography, we imaged E4x12-Cy7 and optoacoustically visualized β-cell insulinoma xenografts in vivo for the first time. In the future, similar optoacoustic tracers that are specific for β-cells and combines optoacoustic and fluorescence imaging modalities could prove to be important tools for monitoring the pancreas for the progression of diabetes.Entities:
Keywords: MSOT; diabetes; exendin-4; near infrared; optoacoustic; sonophore; β-cell imaging
Mesh:
Substances:
Year: 2020 PMID: 33097631 PMCID: PMC8729860 DOI: 10.2967/jnumed.120.252262
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057